Pancreatic Cancer Research

ResearcherJohns Hopkins UniversityActive in the last 2 years

Amy Hacker‐Prietz

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-7877-7093; OpenAlex author ID A5048788581. Sources: OpenAlex.

Their work

Papers
31 (first author 3, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
102
Papers, trials and grants by year

2012: 2 papers · 2013: 3 papers · 2014: 3 papers · 2015: 2 papers · 2016: 2 papers · 2017: 3 papers · 2018: 3 papers · 2019: none · 2020: none · 2021: 3 papers · 2022: 5 papers · 2023: 1 paper · 2024: 1 paper · 2025: 2 papers · 2026: 1 paper

Papers 31

  1. Pancreatic Enzyme Replacement Therapy (PERT) in Pancreatic Cancer: First U.S. Consensus Highlights on Dosing, Management, and Provider Inertia. Co-author DOI 10.1093/oncolo/oyag389↗
  2. Effect of travel distance on utilization of ancillary services among patients with pancreatic ductal adenocarcinoma: A single institution study. Co-author DOI 10.1007/s00520-025-09339-3↗
  3. Phase 1 Study of Adjuvant Allogeneic Granulocyte-Macrophage Colony-Stimulating Factor-Transduced Pancreatic Tumor Cell Vaccine, Low-Dose Cyclophosphamide, and … Co-author DOI 10.1016/j.ijrobp.2024.10.039↗
  4. Variation in outcomes and practice patterns among patients with localized pancreatic cancer: the impact of the pancreatic cancer multidisciplinary clinic. First author DOI 10.3389/fonc.2024.1427775↗
  5. Effectiveness of the nutrition referral system in a multidisciplinary pancreatic cancer clinic. Co-author DOI 10.1007/s00520-023-07795-3↗
  6. High local failure rates despite high margin-negative resection rates in a cohort of borderline resectable and locally advanced pancreatic cancer patients trea… Co-author DOI 10.1002/cam4.4527↗
  7. Multiagent Chemotherapy and Stereotactic Body Radiation Therapy in Patients with Unresectable Pancreatic Adenocarcinoma: A Prospective Nonrandomized Controlled… Co-author DOI 10.1016/j.prro.2022.02.009↗
  8. The Impact of the COVID-19 Pandemic on Multidisciplinary Clinics: A High-Volume Pancreatic Cancer Center Experience. Co-author DOI 10.1067/j.cpradiol.2022.05.001↗
  9. RAD51B Harbors Germline Mutations Associated With Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1200/po.21.00404↗
  10. Neoadjuvant Stereotactic Body Radiotherapy After Upfront Chemotherapy Improves Pathologic Outcomes Compared With Chemotherapy Alone for Patients With Borderlin… Co-author DOI 10.1245/s10434-021-11202-8↗
  11. Challenges of the current precision medicine approach for pancreatic cancer: A single institution experience between 2013 and 2017. Co-author DOI 10.1016/j.canlet.2020.10.039↗
  12. Vaccine-Induced Intratumoral Lymphoid Aggregates Correlate with Survival Following Treatment with a Neoadjuvant and Adjuvant Vaccine in Patients with Resectabl… Co-author DOI 10.1158/1078-0432.ccr-20-2974↗
  13. Impact of somatic mutations on clinical and pathologic outcomes in borderline resectable and locally advanced pancreatic cancer treated with neoadjuvant chemot… Co-author DOI 10.3857/roj.2021.00815↗
  14. Improving prediction of surgical resectability over current staging guidelines in patients with pancreatic cancer who receive stereotactic body radiation thera… Co-author DOI 10.1016/j.adro.2018.07.002↗
  15. Multiplex Proximity Ligation Assay to Identify Potential Prognostic Biomarkers for Improved Survival in Locally Advanced Pancreatic Cancer Patients Treated Wit… Co-author DOI 10.1016/j.ijrobp.2017.10.001↗
  16. Stereotactic Body Radiation Therapy for Isolated Local Recurrence After Surgical Resection of Pancreatic Ductal Adenocarcinoma Appears to be Safe and Effective. Co-author DOI 10.1245/s10434-017-6134-6↗
  17. Long-term survival benefit of upfront chemotherapy in patients with newly diagnosed borderline resectable pancreatic cancer. Co-author DOI 10.1002/cam4.1104↗
  18. A rare case of esophageal metastasis from pancreatic ductal adenocarcinoma: a case report and literature review. Co-author DOI 10.18632/oncotarget.18458↗
  19. What Advanced Practitioners Need to Know About the Diagnosis and Treatment of Patients With Pancreatic Cancer. First author DOI 10.6004/jadpro.2017.8.3.7↗
  20. Lymphocyte-Sparing Effect of Stereotactic Body Radiation Therapy in Patients With Unresectable Pancreatic Cancer. Co-author DOI 10.1016/j.ijrobp.2015.11.026↗
  21. Patient-reported outcomes of a multicenter phase 2 study investigating gemcitabine and stereotactic body radiation therapy in locally advanced pancreatic cance… Co-author DOI 10.1016/j.prro.2016.05.005↗
  22. Phase 2 multi-institutional trial evaluating gemcitabine and stereotactic body radiotherapy for patients with locally advanced unresectable pancreatic adenocar… Co-author DOI 10.1002/cncr.29161↗
  23. The Role of Stereotactic Body Radiation Therapy for Pancreatic Cancer: A Single-Institution Experience. Co-author DOI 10.1245/s10434-014-4274-5↗
  24. Baseline metabolic tumor volume and total lesion glycolysis are associated with survival outcomes in patients with locally advanced pancreatic cancer receiving… Co-author DOI 10.1016/j.ijrobp.2014.02.031↗
  25. Radiosensitization of Pancreatic Cancer Cells In Vitro and In Vivo through Poly (ADP-ribose) Polymerase Inhibition with ABT-888. Co-author DOI 10.1016/j.tranon.2014.04.003↗
  26. Baseline hemoglobin-A1c impacts clinical outcomes in patients with pancreatic cancer. Co-author DOI 10.6004/jnccn.2014.0006↗
  27. Resection of borderline resectable pancreatic cancer after neoadjuvant chemoradiation does not depend on improved radiographic appearance of tumor-vessel relat… First author DOI 10.1007/s13566-013-0115-6↗
  28. Phase 2 study of erlotinib combined with adjuvant chemoradiation and chemotherapy in patients with resectable pancreatic cancer. Co-author DOI 10.1016/j.ijrobp.2013.03.032↗
  29. Understanding the Role of 18Flurodeoxyglucose PET in Predicting Improved Survival in Locally Advanced Pancreatic Cancer. Co-author DOI 10.1016/j.prro.2013.01.090↗
  30. Comparison of conventional and 3-dimensional computed tomography against histopathologic examination in determining pancreatic adenocarcinoma tumor size: impli… Co-author DOI 10.1016/j.radonc.2012.07.004↗
  31. Development of a novel preclinical pancreatic cancer research model: bioluminescence image-guided focal irradiation and tumor monitoring of orthotopic xenograf… Co-author DOI 10.1593/tlo.11316↗

Closest collaborators

The 25 strongest of 102 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Joseph M. Herman · 26 shared papers, 2012–2025 · strength 2.09
  2. Amol Kumar Narang · 16 shared papers, 2017–2025 · strength 2.02
  3. Daniel A. Laheru · 21 shared papers, 2012–2025 · strength 1.48
  4. Lei Zheng · 17 shared papers, 2013–2023 · strength 1.40
  5. Jin Peng He · 12 shared papers, 2017–2023 · strength 1.23
  6. Dung Thi Le · 15 shared papers, 2013–2025 · strength 1.21
  7. Lauren M. Rosati · 12 shared papers, 2015–2025 · strength 0.93
  8. Colin Hill · 6 shared papers, 2021–2025 · strength 0.87
  9. Matthew John Weiss · 11 shared papers, 2015–2022 · strength 0.87
  10. Christopher Lee Wolfgang · 14 shared papers, 2012–2022 · strength 0.76
  11. Ana De Jesus‐Acosta · 11 shared papers, 2013–2022 · strength 0.75
  12. Timothy Michael Pawlik · 12 shared papers, 2012–2025 · strength 0.73
  13. Christopher L. Wolfgang · 7 shared papers, 2016–2025 · strength 0.66
  14. Ralph H. Hruban · 10 shared papers, 2012–2022 · strength 0.60
  15. Elizabeth M. Jaffee · 7 shared papers, 2012–2025 · strength 0.56
  16. Priya Pathak · 2 shared papers, 2024–2025 · strength 0.56
  17. Jing He · 2 shared papers, 2024–2025 · strength 0.56
  18. Shuchi Sehgal · 4 shared papers, 2021–2022 · strength 0.50
  19. Elliot K. Fishman · 8 shared papers, 2012–2022 · strength 0.49
  20. Lei Zheng · 2 shared papers, 2024–2025 · strength 0.46
  21. Richard Andrew Burkhart · 4 shared papers, 2021–2022 · strength 0.42
  22. Abhinav V. Reddy · 3 shared papers, 2021–2023 · strength 0.41
  23. William R. Burns · 4 shared papers, 2021–2022 · strength 0.41
  24. Ding Ding · 4 shared papers, 2021–2022 · strength 0.39
  25. Richard David Schulick · 5 shared papers, 2012–2025 · strength 0.36

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.